Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: 10K a day who wrote (100913)	4/14/2000 10:30:00 PM
From: 10K a day	Read Replies (2) \| Respond to of 164684

Double edge sword. Cuts both ways. Buying On margin. Building strength, Pushing stocks up, Day after day, Small buys, More buying power, Small buys, More buying power, Double edge sword. They were talking about decreasing margin requirements,,, Now they are talking about increasing margin requirments,,, Can't have it both ways... What will it be... Increase Requirements at the bottom... Decrease Requirements at the top....

To: 10K a day who wrote (100913)	4/14/2000 10:55:00 PM
From: Bob Kim	Read Replies (1) \| Respond to of 164684

I guess what i witnessed with INFOSPACE You mean like below? Blodget's done a lot worse research-wise for investors in ATHM: recommended it at $91 then set a price target of $50 and now says breakup value could be $25 or so; or WBVN: recommended it at $29 with $32 target, then lowered target to $30 and now says fair value is around $6. Don't forget Merrill Lynch named ICGE one its Top 10 Tech selections at around $170 even though it had a $62.50 price target. 4/13/00 We reiterate our Buy rating on Infospace (INSP; $55 3/16; D-1-1-9) and view it as a play on wireless. ---- 2 for 1 split---- 4/5/00 Report price=$107 1/2 We re-iterate our Buy/Buy rating and $200 price objective. 4/3/00 Blue-chip internet enabling technology stocks such as Infospace (INSP, $145 7/16, Real Networks (RNWK, $56 15/16, D-2-1-9) and Inktomi (INKT, $195, D-2-1-9) are 20-50% off their 52 week highs. We believe that the current correction particularly provides a buying opportunity. 3/21/00 Report price=$172 1/2 We reiterate our $200 price objective and Buy/Buy rating. (Wow! Magically the price target is now $200) 1/27/00 Report price=$140 We are upgrading our intermediate-term rating on INSP from Accumulate to Buy. Our long-term rating remains Buy. Our price objective of $175 implies a FY 2001 P/S ratio of 95x.